Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Other Non-Current Liabilities (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Other Non-Current Liabilities for 10 consecutive years, with $1.1 billion as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities rose 6647.06% to $1.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 billion through Dec 2025, up 6647.06% year-over-year, with the annual reading at $1.1 billion for FY2025, 6647.06% up from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $1.1 billion at Ultragenyx Pharmaceutical, up from $18.8 million in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $1.1 billion in Q4 2025, with the low at $1.0 million in Q4 2021.
  • Average Other Non-Current Liabilities over 5 years is $461.6 million, with a median of $348.1 million recorded in 2021.
  • The sharpest move saw Other Non-Current Liabilities plummeted 99.7% in 2021, then surged 87008.36% in 2022.
  • Over 5 years, Other Non-Current Liabilities stood at $1.0 million in 2021, then soared by 87008.36% to $875.4 million in 2022, then fell by 1.5% to $862.3 million in 2023, then crashed by 98.03% to $17.0 million in 2024, then skyrocketed by 6647.06% to $1.1 billion in 2025.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $1.1 billion, $18.8 million, and $17.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.